Biology Reference
In-Depth Information
Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT (2002) Exercise training for claudication.
N Engl J Med 347:1941-1951
Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, Hidaka H (2000) Potent effects
of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide
phosphodiesterase isozyme activity. Biochem Pharmacol 59:347-356
Sun B, Le SN, Lin S, Fong M, Guertin M, Liu Y, Tandon NN, Yoshitake M, Kambayashi J (2002)
New mechanism of action for cilostazol: interplay between adenosine and cilostazol in
inhibiting platelet activation. J Cardiovasc Pharmacol 40:577-585
Sun B, Li H, Shakur Y, Hensley J, Hockman S, Kambayashi J, Manganiello VC, Liu Y (2007)
Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using
subtype-selective knockout mice. Cell Signal 19:1765-1771
Takayoshi T, Shinichi O, Ryuzo A, Ryuichi S, Norihiro S, Hisamichi S, Akira F (2001) Effect of
cilostazol on lipid, uric acid and glucose metabolism in patients with impaired glucose
tolerance or type 2 diabetes mellitus: a double-blind, placebo-controlled study. Clin Drug
Investig 21:325-335
Tamai T, Shimada A, Maeda H, Takahashi S, Oida K, Nakai T, Miyabo S (1992) Reduction of low
density lipoprotein by cilostazol in the non-insulin dependent diabetic patient. Jpn Pharmacol
Ther 20:241-248
Thompson WJ, Ashikaga T, Kelly JJ, Liu L, Zhu B, Vemavarapu L, Strada SJ (2002) Regulation of
cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic
AMP phosphodiesterase (PDE4). Biochem Pharmacol 63:797-807
Thompson PE, Manganiello V, Degerman E (2007) Re-discovering PDE3 inhibitors-new oppor-
tunities for a long neglected target. Curr Top Med Chem 7:421-436
Torii H, Kubota H, Ishihara H, Suzuki M (2007) Cilostazol inhibits the redistribution of the actin
cytoskeleton and junctional proteins on the blood-brain barrier under hypoxia/reoxygenation.
Pharmacol Res 55:104-110
Traupe T, Ortmann J, Munter K, Barton M (2003) Endothelial therapy of atherosclerosis and its
risk factors. Curr Vasc Pharmacol 1:111-121
Tsai EJ, Kass DA (2009) Cyclic GMP signaling in cardiovascular pathophysiology and therapeu-
tics. Pharmacol Ther 122:216-238
van Hattum ES, Algra A, Lawson JA, Eikelboom BC, Moll FL, Tangelder MJD (2009) Bleeding
increases the risk of ischemic events in patients with peripheral arterial disease. Circulation
120:1569-1576
Wakida K, Morimoto N, Shimazawa M, Hozumi I, Nagase H, Inuzuka T, Hara H (2006) Cilostazol
reduces ischemic brain damage partly by inducing metallothionein-1 and -2. Brain Res
1116:187-193
Wang S, Cone J, Fong M, Yoshitake M, Kambayashi J, Liu Y (2001) Interplay between inhibition
of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to
treat intermittent claudication. J Cardiovasc Pharmacol 38:775-783
Wang YX, Fitch R, Li W, Werner M, Halks-Miller M, Lillis B, Vergona R, Post J, Sullivan ME,
Verhallen PF (2002) Reduction of cardiac functional reserve and elevation of aortic stiffness in
hyperlipidemic Yucatan minipigs with systemic and coronary atherosclerosis. Vascul Pharma-
col 39:69-76
Wang T, Elam MB, Forbes WP, Zhong J, Nakajima K (2003) Reduction of remnant lipoprotein
cholesterol concentrations by cilostazol in patients with intermittent claudication. Atheroscle-
rosis 171:337-342
Watanabe N, Ishikawa Y, Kitagawa Y, Ozaki M, Takeshita S, Namura H, Kurimoto Y, Yamada S,
Yokoyama M (1996) Effects of cilostazol on the lipid metabolism in patients with hypertri-
glyceridemia. Jpn Pharmacol Ther 24:127-132
Wilson AM, Harada R, Nair N, Balasubramanian N, Cooke JP (2007) L-arginine supplementation
in peripheral arterial disease: no benefit and possible harm. Circulation 116:188-195
Wilson LS, Elbatarny HS, Crawley SW, Bennett BM, Maurice DH (2008) Compartmentation and
compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-
mediated regulation of platelet functions. Proc Natl Acad Sci USA 105:13650-13655
